Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-483 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 5908.091 | 0.9203 | 0.6997 | 0.5109 | |
| BT-483 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 5908.091 | 0.9570 | 0.8352 | 0.5109 | |
| BT-483 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 5908.091 | 0.9655 | 0.8672 | 0.5109 | |
| BT-483 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 5908.091 | 0.9340 | 0.7499 | 0.5109 | |
| BT-483 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 5908.091 | 0.8384 | 0.4165 | 0.5109 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0000853 | uM | 5909.092 | 1.0587 | 1.0380 | 3.0314 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000427 | uM | 5909.092 | 0.9995 | 0.9997 | 3.0314 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.00213 | uM | 5909.092 | 1.0004 | 1.0003 | 3.0314 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0107 | uM | 5909.092 | 1.0163 | 1.0107 | 3.0314 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0533 | uM | 5909.092 | 0.9827 | 0.9885 | 3.0314 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.267 | uM | 5909.092 | 0.9044 | 0.9348 | 3.0314 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 1.33 | uM | 5909.092 | 0.8783 | 0.9162 | 3.0314 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 6.67 | uM | 5909.092 | 0.8282 | 0.8794 | 3.0314 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 33.3 | uM | 5909.092 | 0.5324 | 0.6245 | 3.0314 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000171 | uM | 5910.091 | 1.1227 | 1.0709 | 3.3208 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000853 | uM | 5910.091 | 1.1313 | 1.0757 | 3.3208 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.00427 | uM | 5910.091 | 1.0796 | 1.0467 | 3.3208 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0213 | uM | 5910.091 | 1.1113 | 1.0646 | 3.3208 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.107 | uM | 5910.091 | 0.9928 | 0.9957 | 3.3208 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.533 | uM | 5910.091 | 0.8984 | 0.9365 | 3.3208 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 2.67 | uM | 5910.091 | 0.8845 | 0.9274 | 3.3208 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 13.3 | uM | 5910.091 | 0.7931 | 0.8652 | 3.3208 | |
| BT-549 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 66.7 | uM | 5910.091 | 0.4835 | 0.6069 | 3.3208 | |
| CAMA-1 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 5911.09 | 0.9569 | 0.9220 | 1.1067 | |
| CAMA-1 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 5911.09 | 0.9864 | 0.9753 | 1.1067 |